Chimeron Bio appoints Kevin Heyeck as CEO

– USA, PA –  Chimeron Bio, an RNA company developing self-amplifying RNA vaccines and therapeutics designed on its proprietary ChaESAR RNA delivery platform, today announced the appointment of Kevin Heyeck as CEO, coming with a long and successful track record of executive and entrepreneurial experience in life sciences.

About Kevin Heyeck

Kevin Heyeck began his career at Harvard University’s Office of Technology Licensing, then went on to lead corporate and business development for multiple venture-backed drug discovery companies, and more recently in venture capital as Managing Director of a venture fund investing in early-stage life science companies. In addition to joining the Chimeron Board, his board memberships include Cru Bio, UAMS Bioventures, and previously, Hibercell, Ultivue, and board observer of Iteos. Kevin’s guidance and leadership are informed by more than 25 years of experience starting and growing venture-backed life sciences companies, both in an executive capacity and as a serial entrepreneur.

“Chimeron Bio represents a ground-breaking company deploying a next-generation, foundational technology platform that pushes the frontier of RNA delivery and RNA medicines and will allow us to quickly build a high-impact pipeline that includes pre-clinical studies in oncology, infection disease, and rare disease. I am looking forward to working with Chimeron’s exceptional team to advance the development of its self-amplifying RNA technology across indications using the ChaESAR™ platform to create and deliver innovative RNA medicines that will have a meaningful and positive impact for patients,” said Kevin Heyeck.

About Chimeron Bio

Chimeron Bio is a biotechnology company focused on the research of self-amplifying RNA towards the development of novel RNA drugs and vaccines for various diseases. The company uses its proprietary ChaESAR platform to develop a pipeline in oncology, rare genetic disorders, and infectious diseases. It is developing two COVID-19 vaccine candidates each with its unique mechanism of action. The candidates have substantial promise in early safety assessment and are under further development.

For more information: https://www.chimeron.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.